| State | Name as filed |
|---|---|
| CA | Tempus AI, Inc. |
| State | Agency | Source key | Raw status | Status | Stage | Review type |
|---|---|---|---|---|---|---|
| CA | Office of Health Care Affordability (HCAI) | material-change-transaction-notice-ambry | CMIR Waived | WAIVED | NOTICE | Tempus AI, Inc. will acquire Ambry Genetics Corporation. Both parties previously partnered to distribute germline sequencing for inherited cancer risk and this acquisition intends to further expand inherited risk screening for cancer patients. |
| Date | Date kind | Event | Raw text | Source |
|---|---|---|---|---|
| 2024-12-20 | PUBLISHED | NOTICE_ACCEPTED | Date Submission Completed: December 20, 2024 | CA agency page |
| not dated | PUBLISHED | CMIR_WAIVED | CMIR Waived | CA agency page |
| Source | Captured at (UTC) |
|---|---|
| https://hcai.ca.gov/affordability/ohca/assess-market-consolidation/material-change-transaction-notices-mcn-and-cost-and-market-impact-review-cmir/ | 2026-09-26T11:15:42.293Z |